Clinical Trials Browser

Phase 1 × Neoplasms, Plasma Cell × Dexamethasone × Clear all

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Completed

14 enrolled 15 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03582033 2024-12-24

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Phase 1 Terminated

83 enrolled 57 charts

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Phase 1 Terminated

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00687674 2019-08-20

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Terminated

13 enrolled 7 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01440582 2019-03-04

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01042704 2017-07-31

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Phase 1 Completed

Neoplasms, Plasma Cell

NCT00150462 2017-05-02

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Phase 1 Completed

48 enrolled 26 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT01985477 2016-09-14

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01807286 2016-05-13

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Phase 1 Terminated

Amyloidosis, Neoplasms, Plasma Cell

NCT00258245 2013-04-29

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00089453 2012-04-19

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell